EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease

José María García-Alberca iD, Paz De La Guía, Esther Gris, Silvia Mendoza, María López De La Rica, José Antonio López-Trigo iD, Rosa López-Mongil, Teresa García-López, Raquel López-García, Teresa Rodríguez Del Rey iD, Javier Gay-Puente iD, Jesús García-Castro und 12 weitere

Journal of Alzheimer’s Disease · 2024

DOI: 10.1177/13872877241292018 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von José María García-Alberca und 23 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Research Center and Memory Clinic, Instituto Andaluz de Neurociencia (IANEC), Málaga, Spain. Hauptthemen laut MEDLINE: Rivastigmine, Cholinesterase Inhibitors, Alzheimer Disease, Drug Administration Schedule. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Esteve Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adherence is critical in patients with Alzheimer's disease (AD) in order to achieve optimal benefit from therapy. However, patient compliance with the treatment remains a challenge.

Objective

To evaluate, in a real-world clinical setting, caregiver preference and treatment compliance with twice-weekly versus daily transdermal rivastigmine patch in mild-to-moderate AD.

Methods

92 patients who had been treated with daily rivastigmine patch for at least six months prior to switching to twice-weekly patch were evaluated. The change in therapeutic regimen was decided by the treating physician in accordance with standard practice. Caregivers’ satisfaction with daily rivastigmine patch was assessed at study entry. Caregiver's preference and satisfaction with twice-weekly patch as well as patient compliance were evaluated at weeks 12 and 24 using the Alzheimer's Disease Caregiver Preference Questionnaire.

Results

A significantly higher proportion of caregivers expressed a preference for the twice-weekly patch over the daily patch ( p < 0.001), and this preference was found to be associated with ease of use ( p < 0.001), ease of following the schedule ( p < 0.001), and ease of compliance ( p < 0.001). Furthermore, caregivers were more satisfied with the twice-weekly patch ( p < 0.0001). At 24 weeks, patient compliance was significantly better with the twice-weekly patch than with the daily patch ( p = 0.002). Caregiver burden significantly improved at the end of the treatment ( p = 0.003). No serious adverse events were reported.

Conclusions

The twice-weekly rivastigmine patch offers a convenient and straightforward dosing regimen for caregivers, with potential to enhance adherence with treatment in AD patients without causing serious adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivastigmineCholinesterase InhibitorsAlzheimer DiseaseDrug Administration ScheduleCaregiversProspective StudiesHumansMaleFemaleAgedAged, 80 and overAdultMiddle AgedTransdermal PatchMedication AdherencePatient SatisfactionTime Factors

Stichwörter der Autor:innen

Alzheimer’s diseasecaregiver burdencaregiverspatient compliancerivastigminetransdermal patch

Substanzen

RivastigmineCholinesterase Inhibitors

Autor:innen und Institutionen

  • Alzheimer Research Center and Memory Clinic, Instituto Andaluz de Neurociencia (IANEC), Málaga, Spain.
  • Centro Crevic, Málaga, Spain.
  • Clínica Neurodem, Almería, Spain.
  • Centro de Referencia Estatal de Atención a Personas con Enfermedad de Alzheimer y Otras Demencias, Salamanca, Spain.
  • Ace Alzheimer Center Barcelona, Barcelona, Spain.
  • Hospital del Bierzo, Ponferrada, Spain.

ORCID-Profile: José María García-Alberca, José Antonio López-Trigo, Teresa Rodríguez Del Rey, Javier Gay-Puente, Francisca Rius, Miguel Ángel Barbancho, Encarnación Blanco-Reina

Förderung

  • Esteve Pharmaceuticals

Zitieren

APA

García-Alberca, J. M., De La Guía, P., Gris, E., Mendoza, S., López De La Rica, M., López-Trigo, J. A., López-Mongil, R., García-López, T., López-García, R., Rodríguez Del Rey, T., Gay-Puente, J., García-Castro, J., Casales, F., Morato, X., Boada, M., González-Velasco, G., Marín-Carmona, J. M., Páez, N. I., León, M., …, & Blanco-Reina, E. (2024). Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241292018

Vancouver

García-Alberca JM, De La Guía P, Gris E, Mendoza S, López De La Rica M, López-Trigo JA, et al. Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease. Journal of Alzheimer’s Disease. 2024. doi:10.1177/13872877241292018

BibTeX
@article{GarcaAlberca2024,
  author = {García-Alberca, José María and De La Guía, Paz and Gris, Esther and Mendoza, Silvia and López De La Rica, María and López-Trigo, José Antonio and López-Mongil, Rosa and García-López, Teresa and López-García, Raquel and Rodríguez Del Rey, Teresa and Gay-Puente, Javier and García-Castro, Jesús and Casales, Federico and Morato, Xavier and Boada, Mercè and González-Velasco, Gemma and Marín-Carmona, José Manuel and Páez, Nora Inés and León, María and Carrillejo, Rosario and Rius, Francisca and Barbancho, Miguel Ángel and Lara, José Pablo and Blanco-Reina, Encarnación},
  title = {Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  doi = {10.1177/13872877241292018}
}
Kostenlos starten →